VHL and HIF-1α: Gene variations and prognosis in early-stage clear cell renal cell carcinoma

Medical Oncology

Volumn 31, Issue 3, 2014, Pages

  Lessi, Francesca ^a   Mazzanti, Chiara Maria ^a   Tomei, Sara ^b   Di Cristofano, Claudio ^c   Minervini, Andrea ^d   Menicagli, Michele ^e   Apollo, Alessandro ^e   Masieri, Lorenzo ^d   Collecchi, Paola ^e   Minervini, Riccardo ^e   Carini, Marco ^d   Bevilacqua, Generoso ^e  

^a Pisa Science Foundation   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

ccRCC; HIF 1 ; Renal carcinoma; VHL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VON HIPPEL LINDAU PROTEIN; HIF1A PROTEIN, HUMAN; TUMOR MARKER; VHL PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CANCER PROGNOSIS; CODON; DNA METHYLATION; EARLY CANCER; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; HETEROZYGOSITY LOSS; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84892460418     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0840-8     Document Type: Article

References (29)

1. Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104(5):968-74. doi: 10.1002/cncr.21254.
2. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000;60(7):1942-8.
3. Foster K, Crossey PA, Cairns P, Hetherington JW, Richards FM, Jones MH, et al. Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer. 1994;69(2):230-4.
4. Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA. 1998;95(20):11661-6.
5. Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23(1):18-25. doi: 10.1016/j.semcancer.2012.06.001.
6. 2 sensing. Science. 2001;292(5516):464-8. doi: 10.1126/science. 1059817.
7. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85-90. doi: 10.1038/ng0594-85.
8. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep. 2005;13(5):859-64.
9. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem. 1997;272(35):22322-9.
10. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom Cancer. 1998;22(3):200-9.
11. Di Cristofano C, Minervini A, Menicagli M, Salinitri G, Bertacca G, Pefanis G, et al. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am J Surg Pathol. 2007;31(12):1875-81. doi: 10.1097/PAS.0b013e318094fed8.
12. Kim HO, Jo YH, Lee J, Lee SS, Yoon KS. The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncol Rep. 2008;20(5):1181-7.
13. Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet. 2004;153(2):122-6. doi: 10.1016/j.cancergencyto.2004.01.014.
14. Percy MJ, Mooney SM, McMullin MF, Flores A, Lappin TR, Lee FS. A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. Mol Cancer. 2003;2:31. doi: 10.1186/1476-4598-2-31.
15. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94(20):1569-75.
16. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45(8):860-7. doi: 10.1038/ng.2699.
17. Minervini A, Di Cristofano C, Collecchi P, Salinitri G, Selli C, Bevilacqua G, et al. Intracapsular clear cell renal carcinoma: ploidy status improves the prognostic value of the 2002 TNM classification. J Urol. 2005;174(4 Pt 1):1203-7 Discussion 7.
18. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res. 2003;63(13):3724-8.
19. Hu X, Fang Y, Zheng J, He Y, Zan X, Lin S, et al. The association between HIF-1alpha polymorphism and cancer risk: a systematic review and meta-analysis. Tumour Biol. 2013;. doi: 10.1007/s13277-013-1160-x.
20. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10(18 Pt 2):6282S-9S. doi: 10.1158/1078-0432.CCR- 050013.
21. Minervini A, Lilas L, Minervini R, Selli C. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer. 2002;94(10):2590-5.
22. Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F, Lorenzo-Romero JG, Donate-Moreno MJ, Pastor-Navarro H, et al. Determination of VHL gene mutations in sporadic renal cell carcinoma. Eur Urol. 2006;49(6):1051-7. doi: 10.1016/j.eururo.2005.10.028.
23. Igarashi H, Esumi M, Ishida H, Okada K. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer. 2002;95(1):47-53. doi: 10.1002/cncr.10635.
24. Sukosd F, Kuroda N, Beothe T, Kaur AP, Kovacs G. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res. 2003;63(2):455-7.
25. Velickovic M, Delahunt B, Storkel S, Grebem SK. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res. 2001;61(12):4815-9.
26. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosom Cancer. 2002;34(1):58-68.
27. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002;196(2):186-93. doi: 10.1002/path.1034.
28. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov. 2011;1(3):222-35. doi: 10.1158/2159-8290.CD-11- 0098.
29. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003;24(11):1779-83. doi: 10.1093/carcin/bgg132.